Staging preview: health content pending qualified review
D2C Peptides
Wolverine Stack (BPC-157 + TB-500) vial

Wolverine Stack 10 mg (5 mg + 5 mg)

Also searched as: bpc 157 tb 500, bpc-157 tb-500, wolverine stack, bpc tb500

Sold as BPC-157 + TB-500 Peptide Blend

$60 In stock

Strength
Ships from

For research use only. Not for human or veterinary use.

Ships from the USA or Canada. Shipping details

Wolverine Stack is one research vial of freeze-dried powder holding two synthetic peptides: 5 mg BPC-157, a 15-amino-acid peptide, and 5 mg TB-500, an acetylated 7-amino-acid fragment of thymosin beta-4.12 Neither is part of any FDA-approved drug, and most research on each comes from animals.12

Specifications

Vial contents10 mg (5 mg + 5 mg): 5 mg BPC-157 and 5 mg TB-500 in one vial
Ratio by weight1 to 1 (BPC-157 to TB-500)
FormFreeze-dried (lyophilized) powder holding both peptides
ComponentsBPC-157: synthetic peptide of 15 amino acids (a pentadecapeptide). TB-500: N-acetylated synthetic peptide of 7 amino acids, copied from amino acids 17 to 23 of thymosin beta-4129
Sequence (one-letter code)BPC-157: GEPPPGKPADDAGLV. TB-500: Ac-LKKTETQ49
Sequence (three-letter code)BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH47
Molecular formulaNo single formula for the mixture. BPC-157: C62H98N16O22. TB-500: C38H68N10O1436
Molar massBPC-157: 1419.5 g/mol. TB-500: 889.0 g/mol36
CAS numberListed per peptide. BPC-157: 137525-51-0. TB-500 (free base): 885340-08-9; FDA notes some websites use this number for TB-500 acetate582
PubChem CIDListed per peptide. BPC-157: 9941957. TB-500: 6270766236
Strength10 mg (5 mg + 5 mg)
Ships fromUSA, Canada
CategoryMuscle Growth Peptides
StorageFDA's reviews give storage data for each peptide alone, not for the two mixed.12 Sources cited there keep dry BPC-157 desiccated below -18 °C and dry TB-500 sealed, away from moisture and light, at -20 °C or colder (free base) or below -15 °C (acetate).12

Supplies for Wolverine Stack (BPC-157 + TB-500)

Bulk and wholesale orders

Labs ordering Wolverine Stack in quantity, alone or with the single BPC-157 and TB-500 vials, can apply for wholesale terms, confirmed during the application.

Wholesale detailsApply for a wholesale account

Questions about Wolverine Stack (BPC-157 + TB-500)

About Wolverine Stack (BPC-157 + TB-500)

Wolverine Stack puts two lab-made peptides in one vial. BPC-157 is a 15-amino-acid chain described as a piece of a protein from human gastric juice.1 TB-500 is an acetylated copy of amino acids 17 to 23 of thymosin beta-4, and FDA states that it and thymosin beta-4 are not the same substance.29 This page lists Wolverine Stack for sale as one 10 mg (5 mg + 5 mg) research vial in the muscle growth peptides category.

That is a store category, not a research finding: published studies of these peptides look at healing after tendon, ligament or muscle injury, most of them in animals.1310 The pair has been given together in one 2026 rat study and to 3 patients; 4 others got BPC-157 with thymosin beta-4.101211 Reported reactions, the amounts used in studies and the legal history are covered in What is Wolverine Stack (BPC-157 + TB-500)?

Research highlights

  • Achilles tendon repair, rats (2026): in 32 rats treated for 4 weeks, the pair gave no added benefit over BPC-157 or TB-500 alone.10
  • Same rat study: tendon strength rose significantly (p < 0.05) only with TB-500 alone.10 The rats received six times more TB-500 than BPC-157 by weight, while this vial holds equal amounts.10
  • Knee pain, people (2021 chart review): 3 of 4 patients given knee injections of BPC-157 with thymosin beta-4 reported significant improvement, with no control group.11
  • Jaw nerve injury, people (2026 case series): numbness largely resolved in 3 patients who also got other drugs, and the authors say causality cannot be established.12
  • BPC-157 alone, animals (2025 systematic review): across 35 preclinical injury studies, it improved functional, structural and biomechanical outcomes.13
  • TB-500 alone, cells (2024, summarized by FDA): in fibroblast cultures, it did not make scratch wounds close faster.2

Regulatory status

Neither peptide, in free base or acetate form, is an ingredient of an FDA-approved drug, and neither has its own USP or National Formulary monograph.12 FDA staff assessed both for a July 23, 2026 compounding advisory meeting (BPC-157 for ulcerative colitis, TB-500 for wound healing) and advised against adding either to the 503A Bulks List.1412 Committee members disagreed and backed each one by 8 votes to 6, with 1 abstention.1516 By October 24, 2026, FDA's meeting page listed no final action.14

FDA's 2026 review also found the pair sold together online, including a 10 mg injectable blend and products labeled for research purposes only.1 In 2023, FDA told a seller that its BPC-157 and TB-500 injectables and nasal sprays were unapproved new drugs despite "research purpose only" labels, because its website showed human use.17 WADA bans BPC-157 (class S0) and TB-500 (class S2.3) in and out of competition.18 For research use only. Not for human or veterinary use.

Handling and storage

In water, BPC-157 dissolves to 5 mg/mL and TB-500 free base to 50 mg/mL, by supplier figures quoted in FDA's two reviews.12 The reviews also caution that pH, heat, high concentration and impurities can cause peptides like these to aggregate or break down.12 Because a single volume of diluent dissolves both, the two always end up at equal strength: 5 mg divided by that volume. The reconstitution calculator works out the figures, and the reconstitution guide sets out the lab steps.

Frequently asked questions

Where can I buy the Wolverine stack?

On this page, as one 10 mg (5 mg + 5 mg) research vial shipped from the USA and Canada to addresses across the United States. The selector at the top shows stock for each origin. Neither peptide is part of an FDA-approved drug, so the vial is a research chemical, not a medicine.12 The shipping and returns pages give delivery and return terms.

What strength is the vial, and what is the Wolverine stack price?

One strength is listed: 10 mg (5 mg + 5 mg), meaning 5 mg each of BPC-157 and TB-500 in one powder. The Wolverine stack price for it is $60, shown with stock for each origin in the selector. Single vials of BPC-157 ($30) and TB-500 ($45) are also listed.

How should the vial be stored when it arrives?

Store it sealed, dry and frozen. Supplier data cited by FDA give dry BPC-157 about 3 weeks of stability at room temperature, with desiccated storage below -18 °C advised for longer periods.1 For dry TB-500 free base, a vendor data sheet cited by FDA gives 1 year at -20 °C.2 Freezer practice is in the storage guide.

Does the Wolverine stack come with a certificate of analysis?

Testing paperwork, where available, is on the lab results page. For a blend, check that the certificate identifies and measures both peptides, not just overall purity. That matters because FDA calls TB-500 a common name rather than an official drug name, with different molecules sold under it.2 PubChem lists molar masses of 1419.5 g/mol for BPC-157 and 889.0 g/mol for TB-500.36

What supplies are used with this vial?

The powder is mixed with a diluent such as bacteriostatic water before lab work. The listed supplies also include alcohol swabs, a 3 mL Luer-Lok syringe, insulin syringes and an 18G 1-inch needle. The reconstitution guide covers their laboratory handling only.

Is the Wolverine stack for human use?

No. It is offered for laboratory research only. The 2026 FDA review found no published report of TB-500 given to a person.2 USADA says no safe dose of BPC-157 is known, since it is so little studied in humans.19 One FDA adverse event report links a research-labeled injection with the same 5 mg of each peptide to skin and gum darkening.1

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), dated 5/11/2026. U.S. Food and Drug Administration, 2026.
  2. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Evaluation of TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), dated 5/15/2026. U.S. Food and Drug Administration, 2026.
  3. PubChem Compound CID 9941957 (Bpc-157): computed properties. PubChem, National Library of Medicine (NIH), 2026.
  4. PubChem Compound CID 9941957 (Bpc-157): synonyms. PubChem, National Library of Medicine (NIH), 2026.
  5. PubChem Compound CID 9941957 (Bpc-157): CAS registry number (sources ChemIDplus, DrugBank, EPA DSSTox). PubChem, National Library of Medicine (NIH), 2026.
  6. PubChem Compound CID 62707662 (TB-500, record title Unii-qhk6Z47gtg): computed properties. PubChem, National Library of Medicine (NIH), 2026.
  7. PubChem Compound CID 62707662 (TB-500): synonyms. PubChem, National Library of Medicine (NIH), 2026.
  8. PubChem Compound CID 62707662 (TB-500): CAS registry number (source ChemIDplus). PubChem, National Library of Medicine (NIH), 2026.
  9. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential (Esposito S, et al.; PMID 22962027). Drug Testing and Analysis, 2012.
  10. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Biçer O, Adanir O, et al.; PMID 42542926). Joint Diseases and Related Surgery, 2026.
  11. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Lee E, Padgett B; PMID 34324435). Alternative Therapies in Health and Medicine, 2021.
  12. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases (Froum S, et al.; PMID 42876687). Frontiers in Oral Health, 2026.
  13. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi N, et al.; PMID 40756949). HSS Journal, 2025.
  14. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of 08/06/2026). U.S. Food and Drug Administration, 2026.
  15. FDA committee recommends looser restrictions for several peptides (Bascom E, July 24, 2026). Healio, 2026.
  16. FDA advisory committee backs two controversial peptides (Eglovitch JS, 23 July 2026). Regulatory Affairs Professionals Society (RAPS), 2026.
  17. Warning Letter: Warrior Labz SARMS, MARCS-CMS 655280 (June 12, 2023). U.S. Food and Drug Administration, 2023.
  18. World Anti-Doping Code International Standard: Prohibited List 2026 (official English text, hosted by the International Testing Agency). World Anti-Doping Agency (WADA), 2025.
  19. BPC-157: Experimental Peptide Creates Risk for Athletes (undated page; references the July 2026 FDA review). U.S. Anti-Doping Agency (USADA), 2026.
Shop all peptidesMore muscle growth peptides